hematological response to frontline treatment in lr-mds is associated with better os
Published 6 months ago • 132 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
9:25
mgus diagnosis: a step-by-step approach
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
4:28
gern stock gern geron coporation top stocks to buy in september
-
2:48
validation of iwg 2023 criteria for response to treatment with hma in hr-mds
-
2:21
unmet needs in lr-mds: rbc transfusion-dependence
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
2:16
current and future treatment approaches for hr-mds
-
0:55
the role of rna modifications in mds and aml
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
1:17
phase ii study of tosedostat in mds
-
2:33
insights into the results and implications of the commands & imerge studies in lr-mds
-
1:57
enhancing clinical care in lr-mds: managing symptomatic/transfusion-dependent anemia
-
3:36
the genetic landscape of mds: how this is improving & impacting the development of therapies